News

Early, one-year data from the Phase 3 CHORDS study show that Ocrevus effectively prevents relapses and disease progression in relapsing-remitting multiple sclerosis (RRMS) patients who have had poor responses to other disease-modifying therapies. These interim results were presented at the 2019 annual meeting of the American Academy of Neurology (AAN) in…

Aubagio taken as 14 milligram (mg) tablet once daily significantly reduces the risk of relapse in people with relapsing multiple sclerosis (MS) over time irrespective of their prior treatment history, a pooled analysis of Phase 2 and Phase 3 trial results show. The findings were presented at the 2019…

Exposure to interferon beta does not seem to increase the risk of complications during pregnancy in women with multiple sclerosis (MS), new research suggests. The data were presented in an oral presentation, “Pregnancy and Infant Outcomes with Interferon Beta: Data from the European Interferon Beta Pregnancy Registry and MS…

Patients with relapsing-remitting multiple sclerosis (RRMS) who switched to infusions with Sanofi Genzyme’s Lemtrada (alemtuzumab) report increased satisfaction with treatment and improvements in health-related quality of life, according to…

Oral treatment with ozanimod (RPC1063), an investigational immunomodulator under development by Celgene, is better at preventing brain volume loss, compared with Avonex (interferon-beta-1a), in adults with relapsing forms of…

Adamas Pharmaceuticals announced the study design and baseline characteristics of patients enrolling in the company’s ongoing Phase 3 trial testing the efficacy and safety of ADS-5102 (amantadine) extended-release capsules in patients with multiple sclerosis (MS) who have difficulty walking. The data were presented in a poster,…

Higher exposure to Ocrevus (ocrelizumab) is associated with greater immune B-cell depletion in the blood, and lessened risk of disability progression in patients with relapsing multiple sclerosis (MS) and primary progressive disease (PPMS), according to new research. The study supporting that finding, “Pharmacokinetics, Pharmacodynamics and…

A newly developed scoring tool enables better identification of patients with relapsing-remitting multiple sclerosis (RRMS) as well as those transitioning or already diagnosed with secondary progressive MS (SPMS). The research about that finding, “Validation of the Scoring Algorithm for a Novel Integrative Secondary Progressive Multiple Sclerosis (SPMS) Screening Tool,”…

Treatment with Mayzent (siponimod) provided sustained improvements and prevented deterioration of cognitive processing speed in patients with secondary progressive multiple sclerosis (SPMS), regardless of their cognitive function prior to therapy, according to results of a Phase 3 clinical trial. The data were presented at the recent 2019 American…

Quanterix is leading the research presented at this year’s American Academy of Neurology (AAN) Annual Meeting, validating the use of neurofilament light chain (NfL) as a potential biomarker for the diagnosis, prognosis, and treatment monitoring of patients with multiple sclerosis (MS) and other neurodegenerative diseases. The company…

New data suggests that treatment with Tysabri (natalizumab) in an extended interval dosing regimen is associated with a significantly lower risk of progressive multifocal leukoencephalopathy (PML) in patients with multiple sclerosis (MS), compared with the standard interval dosing. The data was presented by Lana Zhovtis Ryerson, MD, on May 7 at the 2019 …

New research suggests that even though pregnant women with multiple sclerosis (MS) are often viewed as high risk by their physicians, pregnancy  does not seem to increase the likelihood of adverse obstetrical outcomes for those patients or their babies. The research was presented at the 2019 Annual Meeting…

Treatment with Tysabri (natalizumab) lowers the levels of the biomarker serum neurofilament light chain (sNfL) in patients with secondary progressive multiple sclerosis (SPMS), according to data from a Phase 3 trial. Findings also revealed that higher levels of sNfL correlated with MS lesions and disease activity prior to starting the…

Treatment with Mayzent (siponomod) may reduce myelin deterioration by lessening the accumulation of immune cells in brain meninges, and preventing the migration of pro-inflammatory lymphocytes into the brain, according to a study in a mouse model of multiple sclerosis (MS). The research, “A Mouse Model of…

Infusible disease-modifying treatment — that is, therapies given intravenously — might have greater benefits for younger people with multiple sclerosis (MS) than oral ones, new research suggests. The research was presented at the ongoing American Academy of Neurology (AAN)’s annual meeting (May 4-10) by Brandi Vollmer,…

A bird in flight, a field of flowers, a dog surrounded by butterflies, a portrait of a toddler — they’re all part of the artwork by the multiple sclerosis (MS) community done for a Multiple Sclerosis Association of America (MSAA) showcasing program, now marking its 10th year. Through its…

A trend of rapidly increasing costs for disease-modifying therapies (DMTs) used to treat multiple sclerosis (MS) appear to be the primary driver behind the overall rise in healthcare costs for people with MS, a study suggests. These data were presented in a…

As his moniker suggests, multiple sclerosis (MS) patient Paul Pelland is in it for the long haul. Known as “Longhaulpaul,” Pelland recently set a world motorcycling endurance record — his third — on a dynamometer while raising $18,500 for MS research and patient support. Pelland rode his Yamaha Star Venture for…

A new clinical application prototype that uses machine learning to help physicians predict the best treatment options for patients with multiple sclerosis (MS) will be unveiled at the American Academy of Neurology’s 2019 annual meeting May 4–10, in Philadelphia, Pennsylvania. The prototype is called PIN Population Data Platform. It has been…

Giving estrogen to two different adult mouse models of multiple sclerosis (MS), including the experimental autoimmune encephalomyelitis (EAE) model, promoted remyelination, a new study shows. Exposure to the hormone affected gene activity in oligodendrocytes, tricking them into producing myelin (the fatty substance that protects nerve cells, and that is destroyed…

Women with multiple sclerosis (MS) are more likely to experience sexual dysfunction and sexual distress than those without the disease, a study reports. According to researchers, the high prevalence of sexual problems among these women may be linked to their age, degree of physical disability, and depression. The…

Retrospective comparison between children with multiple sclerosis (MS) and those with related acute demyelinating syndromes (ADS) highlights the implications of fatigue, depression, and quality of life in these patients. Those are the findings from a study, “Fatigue, depression, and quality of life in children with multiple sclerosis: a…

A subset of stem cells in hair follicles, called melanocytes, appear to do more than just give rise to mature melanocytes, cells that help to determine hair color. Those melanocyte stem cells, or McSCs, that carry the CD34 protein were found in hair follicles from mice to differentiate into glia cells…

A study suggests that it may be possible to create synthetic speech based on recordings of brain activity in people with irreversible speech loss due to neurological ills, such as multiple sclerosis (MS), Parkinson’s, or stroke. The system uses tiny electrodes implanted on the surface of the brain that directly records…

High levels of satisfaction with the efficacy and convenience of Aubagio (teriflunomide), an oral treatment for relapsing multiple sclerosis (MS), were reported by patients across the U.S. and 13 other countries, a post-hoc analysis of data from a real-world Phase 4 study found. The study “Teriflunomide real-world evidence: Global…

An active form of vitamin D can modulate the activity of immune cells and prevent autoimmune reactions known to be involved in several human diseases such as multiple sclerosis (MS). A study with that finding, led by researchers from The University of Edinburgh in Scotland, reveals a new layer…

Cellular senescence — the process of aging at the cellular level — may play a role in the development of primary progressive multiple sclerosis (PPMS) by limiting the ability of myelin-producing cells (oligodendrocytes) to renew and mature. The study with that finding, “Cellular senescence in progenitor…

In clinical practice, relapse events dropped by roughly half over a four-year period in relapsing-remitting multiple sclerosis (RRMS) patients treated with Aubagio (teriflunomide), a real-world study reports. The study, “Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study,” also examined patients’ perspectives in…

The Multiple Sclerosis (MS) Trust, a charity organization that provides support to MS patients in the United Kingdom, is urging them to remain active and find ways to introduce physical activity into their daily routine, as part of its “Move it for MS” campaign. The organization’s…

Researchers have developed a compound based on the thyroid hormone T3 that is able to repair damaged myelin in the brain of mice, a discovery that holds promise for healing myelin loss in patients with multiple sclerosis (MS), results of an early study reveal.